Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2013-12-01 Capital/Financing Update
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Sale of HI-164OV Hunter Immunology Pty Ltd 2 pages 236.7KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the divestment of a research program and intellectual property to another company. It details the terms of the transaction, including cash, equity, deferred consideration, and royalties. There is no indication that this is a full financial report, audit, or earnings release. It is not a regulatory filing or certification. The content focuses on a capital transaction involving sale of assets and equity consideration, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not announcing a report publication, so it is not RPA. Therefore, the best classification is CAP with high confidence.
2013-12-01 English
Bioxyne Limited CEO Steps Down 1 page 184.1KB
Board/Management Information Classification · 95% confidence The document is a short announcement dated 2 December 2013 from Bioxyne Limited regarding the stepping down of its CEO following a non-binding Heads of Agreement to sell a project and intellectual property. It mentions interim management arrangements and expresses thanks to the departing CEO. There is no financial data, no detailed report, no regulatory form references, and the content is about a management change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. The document length is short (1122 characters), consistent with a brief announcement rather than a full report.
2013-12-01 English
Results of 2013 AGM 2 pages 421.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a letter addressed to the Australian Securities Exchange Compliance, dated 29 November 2013, reporting the results of resolutions passed at the Annual General Meeting held on the same day. It lists voting outcomes for multiple resolutions including adoption of the remuneration report, election of directors, and approval of additional placement capacity. The document does not contain financial statements or detailed report content but solely announces the voting results of the AGM. The document length is short (2087 characters) and it explicitly states the results of shareholder votes. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2013-11-28 English
Notice of Extraordinary General Meeting/Proxy Form 29 pages 628.9KB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'Notice of Extraordinary General Meeting and Explanatory Memorandum' for Bioxyne Limited. It includes details about the meeting date, venue, proxy voting instructions, resolutions to be voted on, and explanatory notes about the matters to be considered at the meeting. The content focuses on shareholder voting matters, share placements, director fees in shares, and related party transactions. There is no financial statement or detailed financial analysis present, nor is this a transcript or presentation. The document is clearly a notice and explanatory memorandum for an Extraordinary General Meeting (EGM), which is a type of shareholder meeting notice. This fits the category of Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to solicit their votes on specific resolutions at the meeting. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a simple announcement or regulatory filing. Therefore, the correct classification is PSI with high confidence.
2013-11-21 English
Response to ASX query 4 pages 392.5KB
Regulatory Filings Classification · 95% confidence The document is a letter from Bioxyne Limited responding to an ASX enquiry regarding the company's Appendix 4C for the quarter ended 30 September 2013. Appendix 4C is a quarterly cash flow report required by the ASX for certain companies. The letter addresses questions about cash flow, compliance with listing rules, and future funding plans. The content is a regulatory response to an ASX query about a quarterly report, not the report itself. The document is about compliance and disclosure related to a quarterly cash flow report, which fits best under Regulatory Filings (RNS) as it is a regulatory response and not the actual quarterly report or earnings release. The document length (7934 characters) and content confirm it is not a brief announcement or a full financial report but a detailed regulatory correspondence.
2013-11-05 English
Notice of Annual General Meeting/Proxy Form 16 pages 494.9KB
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) for Bioxyne Limited, including an Explanatory Memorandum and Proxy Form. It details the agenda for the AGM scheduled on 29 November 2013, including the tabling of the Annual Report for the year ended 30 June 2013, adoption of the Remuneration Report, and re-election of directors. The document is not the Annual Report itself but rather the official notice and explanatory materials for the AGM. It contains detailed information about the meeting, resolutions to be voted on, and procedural instructions for shareholders. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document length (15,000 characters) and content confirm it is not a brief announcement or a certification but a full AGM notice and explanatory memorandum.
2013-10-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.